DOCSLIB.ORG

Public Assessment Report Scientific Discussion Irinotecan “BMM Pharma”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Public Assessment Report Scientific Discussion Irinotecan “BMM Pharma” Public Assessment Report Scientific discussion Irinotecan “BMM Pharma” 20 mg/ml concentrate for solution for infusion Irinotecan hydrochloride trihydrate DK/H/1065/001/DC This module reflects the scientific discussion for the approval of Irinotecan “BMM Pharma”. The procedure was finalised on 8 November 2007. For information on changes after this date please refer to the module ‘Update’. 1/5 I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Irinotecan “BMM Pharma” 20 mg/ml concentrate for solution for infusion, from BMM Pharma AB. The product was authorised in Denmark on 3 January 2008. The product is indicated for the treatment of advanced colorectal cancer: In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced cancer. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan- including cytotoxic therapy. Irinotecan is a well-known antineoplastic agent for parenteral use (ATC code L 01 XX 19). It is a specific inhibitor of DNA topoisomerase I and thus cytotoxic. This decentralised procedure concerns a generic application claiming essential similarity with the reference product Campto which has been registered in Denmark since 16 July 1998 by Pfizer ApS. The marketing authorisation is granted based on article 10.1 of Directive 2001/83/EC. II. QUALITY ASPECTS II.1 Introduction Each ml contains 20 mg irinotecan hydrochloride trihydrate, equivalent to 17.33 mg irinotecan. Irinotecan “BMM Pharma” 2 ml contains 40 mg irinotecan hydrochloride trihydrate. Irinotecan “BMM Pharma” 5 ml contains 100 mg irinotecan hydrochloride trihydrate. The product is a clear, colourless to pale yellow solution. The product is packed in 5 ml Type 1 amber glass vials with rubber closures and flip off tear off aluminium seals. Each pack contains 1 vial. However, not all pack sizes may be marketed. The product must be diluted before use and is for single use only. The product contains: Sorbitol; Lactic acid; Sodium hydroxide (to adjust to pH 3.5) and Water for injections. Compliance with Good Manufacturing Practice The RMS has been assured that acceptable standards of GMP (see Directive 2003/94/EC) are in place for this product type at all sites responsible for the manufacturing of the active substance as well as for the manufacturing and assembly of this product prior to granting its national authorisation. II.2 Drug Substance INN: Irinotecan hydrochloride trihydrate Chemical name(s): [1,4’-Bipiperidine]-1’-carboxylic acid (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4- hydroxy-3,14-dioxo-1H-pyrano [3’,4’ : 6,7] indolizino [1,2-b]quinolin-9-yl ester. 2/5 Molecular formula: C33H38N4O6 * HCl * 3 H2O Molecular mass: 677.20 Molecular structure: Irinotecan hydrochloride trihydrate is a pale yellow to yellow coloured powder soluble in dimethyl sulphoxide. The Irinotecan molecule is optically active, with one chiral centre. Irinotecan hydrochloride trihydrate does not exhibit polymorphism. Irinotecan hydrochloride trihydrate is not described in the European Pharmacopoeia (Ph.Eur.) and information on this substance has been provided in the form of an EDMF. Information on the 3 step synthesis of irinotecan hydrochloride trihydrate from starting materials is provided. Specifications for both starting materials and intermediate products are provided and are acceptable. The drug substance specification is compliant with general ICH and Ph.Eur. requirements for drug substances. Stability data are presented supporting a retest period of two years when stored at 2 – 8 C. Irinotecan hydrochloride trihydrate is photostable. II.3 Medicinal Product The product composition has been properly presented. Product development has been described, the choice of excipients justified and their functions explained. Although stable to heating in an autoclave, the product is prepared by aseptic processing. Sterilisation procedures are satisfactorily validated. The manufacturing site is currently being expanded to include terminal sterilisation processing and is expected to be operational within a year. Irinotecan 20mg/ml solution will be manufactured using terminal sterilisation once this processing is implemented. Compatibility studies with 5% dextrose solution and 0.9 % sodium chloride solution have been performed with satisfactory results. The product specifications cover appropriate parameters for this dosage form. Validations of the analytical methods have been presented. Batch analysis has been performed on 3 batches. The batch analysis results show that the finished product meets the proposed specifications. Satisfactory stability data are presented to support a proposed shelf-life of 2 years with the storage precaution “Keep the vial in the outer carton in order to protect from light. Do not freeze”. Chemical and physical in-use stability has been demonstrated in glucose 5% and sodium chloride 0.9% for 24 hours at 2-8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8°C. A commitment has been made to perform temperature cycling studies to ensure that product may be transported satisfactorily from the manufacturing site to the batch release site by different transport means. 3/5 III. NON-CLINICAL ASPECTS This product is a generic formulation of Campto, which is available on the European market. No new preclinical data have been submitted, and therefore the application has not undergone preclinical assessment. This is acceptable for this type of application Environmental risk assessment The product is intended as a substitute for other identical products on the market. The approval of this product will not result in an increase in the total quantity of irinotecan released into the environment. It does not contain any component, which results in an additional hazard to the environment during storage, distribution, use and disposal. IV. CLINICAL ASPECTS IV.1 Introduction Irinotecan is a well-known active substance with established efficacy and tolerability. The product is to be administered as an aqueous intravenous solution containing the same active substance in the same concentration as the reference product. Thus in accordance with the Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98), bioequivalence studies are not requested. IV.2 Risk management plan & Pharmacovigilance system Irinotecan was first approved in 1995, and there is now more than 10 years post-authorisation experience with the active substance. The safety profile of irinotecan can be considered to be well established and no product specific pharmacovigilance issues were identified pre- or postauthorisation which are not adequately covered by the current SPC. Additional risk minimisation activities have not been identified for the reference medicinal product. The MAH has a pharmacovigilance system at their disposal, which is based on the current European legislation. The Pharmacovigilance system described fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the identification and notification of any potential risks occurring either in the Community or in a third country. V. PRODUCT INFORMATION SmPC and Package leaflet The content of the SmPC and package leaflet approved during the decentralised procedure is in accordance with that accepted for the reference product Campto marketed by Pfizer ApS. Readability test The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the PIL was Swedish. The test consisted of a pilot test with 2 participants, followed by two rounds with 10 participants each. The questions covered the following areas sufficiently: traceability, comprehensibility and applicability. 4/5 The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION Irinotecan “BMM Pharma” 20 mg/ml concentrate for solution for infusion has a proven chemical- pharmaceutical quality and is a generic form of Campto. Campto is a well-known medicinal product with an established favourable efficacy and safety profile. The product is to be administered as an aqueous intravenous solution containing the same active substance in the same concentration as the Brand Leader. Thus in accordance with the Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98), no bioequivalence studies are not requested. The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations. The SmPC, package leaflet and labelling are in the agreed templates and are in agreement with other irinotecan containing products. Agreement between Member States
Load more

Recommended publications
  • R&D Briefing 76
    The Impact of Recent Regulatory Developments on the Mexican Therapeutic Landscape Access to innovative medicines is key to El acceso a medicamentos innovadores es clave para improving overall population health, reducing mejorar la salud de toda la población, para reducir los hospitalisation time and decreasing morbidity and tiempos de hospitalización, la morbilidad y la mortalidad mortality. An efficient regulatory process can be de un país. Un proceso regulatorio eficiente tiene un reflected in measurable positive health impacts; impacto positivo medible en la salud, y por el contrario, conversely, activities that slow or impede acciones que retrasan o impiden la eficiencia regulatoria y regulatory efficiency and predictability can be su predictibilidad pueden ser perjudiciales. La parálisis detrimental. Recent developments in the Mexican reciente del Sistema regulatorio mexicano respecto a la regulatory system for the assessments of evaluación de nuevos medicamentos innovadores innovative new products have had a negative conlleva un impacto negativo en la salud de la población impact on Mexican public health. mexicana. This Briefing addresses the impact of suspending Este informe analiza el impacto de la suspensión de las the activities of the New Molecules Committee actividades del Comité de Moléculas Nuevas (NMC, por (NMC) on the Mexican therapeutic landscape. sus siglas en inglés) sobre el horizonte terapéutico de First, we compared the way that “new medicines” México. En primer lugar, comparamos la definición de are defined within the context of the Mexican nuevos medicamentos según el contexto regulatorio regulatory system, with definitions used by mexicano con las definiciones adoptadas por otras comparable regulators and health organisations. agencias reguladoras u organizaciones de salud del We have also investigated the extent to which mundo.
    [Show full text]
  • Renal Clinical Pharmacy Services“
    DISSERTATION „Renal clinical pharmacy services“ Mag.pharm. Gunar Stemer angestrebter akademischer Grad Doktor der Naturwissenschaften (Dr.rer.nat.) Wien, 2011 Studienkennzahl lt. Studienblatt: A 091 449 Dissertationsgebiet lt. Studien- Pharmazie blatt: Betreuerin / Betreuer: Ao. Univ. Prof. Mag. Dr. Rosa Lemmens 2 e pensando di lei mi sopragiunse uno soave sonno ego dominus tuus vide cor tuum e d’esto core ardendo cor tuum lei paventosa umilmente pascea appreso gir io ne vedea piangendo la letizia si convertia in amarissimo pianto io sono in pace cor meum io sono in pace vide cor meum Dante Alighieri La Vita Nuova ~1293 Gewidmet meinen Eltern Annelies und Franz, in aufrichtiger Dankbarkeit und Liebe Dedicated to my parents Annelies and Franz, in sincere gratitude and love 3 4 ACKNOWLEDGEMENTS This thesis would not have been possible without the continuous support, help, and contributions of so many colleagues, companions, friends, and beloved family members. First, I want to express my deepest gratitude to my doctoral advisor, Mrs. Prof. Rosa Lemmens, for her commitment in supervising my thesis work, her support during the writing of this thesis, several constructive discussions with her, and her critical comments. My sincerest thanks are extended to the head of the pharmacy department of the Vienna General Hospital, Mrs. SR Mag. Elfriede Dolinar, for providing me with this unique opportunity to work on the topic of clinical pharmacy and, thus, contribute to the evolution of the complete hospital pharmacy and clinical pharmacy discipline in Austria. I would like to thank her for her trust in my capabilities to succeed in this demanding project over the last three years by implementing new services, her vision regarding the discipline of hospital pharmacy, her overall contribution to the development of the profession of hospital pharmacy, and her continuous belief in the value of clinical pharmacy services.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Etoposide ”Ebewe ” 20 mg/ml – Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 20 mg of etoposide. 1, 5, or 10 vials of 2.5 ml concentrate for solution for infusion contains 50 mg etoposide. 1, 5, or 10 vials of 5 ml concentrate for solution for infusion contains 100 mg etoposide. 1, 5, or 10 vials of 10 ml concentrate for solution for infusion contains 200 mg etoposide. 1, 5, or 10 vials of 20 ml concentrate for solution for infusion contains 400 mg etoposide. 1, 5, or 10 vials of 50 ml concentrate for solution for infusion contains 1000 mg etoposide. Excipients: Benzyl alcohol, ethanol. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, light yellow solution. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Etoposide is a antineoplastic agent for intravenous use. It can be used alone or in combination with other oncolytic agents. Available data show that etoposide may be used in treatment of small -celled lung cancer, resistant non -seminomatous testicular carcinoma, acute myelomonocytic and myelocytic leukaemia (AML, FAB subtype M4 or M5) as part of combination therapy after failure of induction chemotherapy. 4.2 Posology and method of administration Etoposide should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents. Pregnant personnel should not handle chemotherapeutic agents.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • International Price Comparison of Pharmaceuticals 2017
    International price comparison of pharmaceuticals 2017 – a volume based analysis of Swedish pharmaceutical prices and volumes relative to 19 other European coun- tries. 2 (101) You are welcome to quote Dental and Pharmaceutical Benefits Agency reports, but please remember to cite the source: the report’s name, year and Dental and Phar- maceutical Benefits Agency. Dental and Pharmaceutical Benefits Agency, February 2018 Authors: Emil Aho, Pontus Johansson and Gunilla Rönnholm. Reference number: 3611/2017 Postal address: Box 22520, 104 22 Stockholm Visiting address: Fleminggatan 18, Stockholm Telephone: +46 8 568 420 50 www.tlv.se 3 (101) Preface The Dental and Pharmaceutical Benefits Agency’s (TLV’s) mandate includes moni- toring and analysing the price development of pharmaceuticals from an interna- tional perspective. In this report, TLV presents the results of the analysis of price and volume data for the first quarter of 2014, 2015, 2016 and 2017 in Sweden in comparison with 19 other European countries. The segments analysed are pharmaceuticals not exposed to competition and pharmaceuticals exposed to competition, with the latter includ- ing all pharmaceuticals available as substitutable medicines in the product-of-the- month system as per March 2017. The report should be viewed as a basis for further analysis of the dynamics of Swe- dish prices and price changes compared to that seen internationally. Sofia Wallström Director-General 4 (101) 5 (101) Table of contents Preface ..................................................................................................................
    [Show full text]
  • A Plea to Systematically Assess the Real-World Cost-Effectiveness Of
    Erasmus Universiteit Rotterdam Handling uncertainty: a plea to systematically assess the real-world cost-effectiveness of expensive outpatient medicines Cost-effectiveness review and critical evidence appraisal for pharmaceutical products potentially benefitting most from unrevised reimbursement in the Netherlands Frank G. Sandmann [Rotterdam, November 2011] - i - A thesis submitted to the Institute of Health Policy and Management at the Erasmus University Rotterdam, the Netherlands, in partial fulfilment of the requirements for the degree of Master of Science in Health Economics, Policy and Law with a specialisation in ‘ Health Economics ’. Rotterdam, 30 November 2011 Thesis Supervisor Dr. Marc Koopmanschap – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Co-Readers Prof. dr. Adri Steenhoek – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Dr. Ken Redekop – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Frank Gerd Sandmann Student of Health Economics (349997) Institute of Health Policy and Management (iBMG) & Erasmus School of Economics (ESE) Erasmus University Rotterdam, Rotterdam, The Netherlands - ii - Dedication Gewidmet meinen Großeltern Margret und Josef Feilen. - iii - Acknowledgements I would like to thank my daily supervisor Marc Koopmanschap for his comments, expertise, and kind supportive attitude. You truly mastered the ‘open-door’ policy and I always felt good taken care of. A positive outlook on life can make a lot look so much easier than expected. I also highly value the effort from Wil Toenders for his comments on a preliminary concept version of the text parts for the two medications imatinib and pegfilgrastim. I would like to thank Adri Steenhoek and Margreet Franken. Our work was inspiration for me and this thesis! My great sense of appreciation goes to my friends Clare Ninsiima, René Miller, and Ilja Löwen.
    [Show full text]
  • Utilization and Expenditure of Anti-Cancer Medicines in Kosovo: Findings and Implications
    PharmacoEconomics Open (2018) 2:423–432 https://doi.org/10.1007/s41669-017-0066-8 ORIGINAL RESEARCH ARTICLE Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications 1,2 3,4,5 5 5 Arianit Jakupi • Brian Godman • Antony Martin • Alan Haycox • Indrit Baholli6 Published online: 2 February 2018 Ó The Author(s) 2018. This article is an open access publication Abstract Method National drug utilization data is available in Background and Objective The Ministry of Health (MoH) Kosovo. Utilization and expenditure on anti-cancer leads and organizes health policy in Kosovo, which medicines [Anatomical Therapeutic Chemical (ATC) code includes procurement and provision of medicines, includ- L], initially from 2011 to 2013, especially for anti-cancer ing anti-cancer medicines, which compose a special group medicines on the essential medicines list was analysed of medicines. However, there has been limited analysis of from national data. In addition, current systems for the utilization and expenditure on anti-cancer medicines in procuring and managing anti-cancer medicines in Kosovo Kosovo; consequently, the objective of this study is to was documented. undertake research to provide future guidance on the use of Results There was appreciable variability in the utilization anti-cancer medicines. of anti-cancer medicines over the years, with low or limited use of some anti-cancer medicines on the Essential Medi- cine List. This is a concern in view of their essential & Brian Godman medicine status. From 2011 to 2013, €16.49 million was [email protected]; [email protected]; spent on anti-cancer medicines (ATC L).
    [Show full text]
  • Jatros-2018-02
    EUR 9,– Jahrgang 23/2018 Österreichische Post AG, MZ 09Z038204M, Retouren an PF555, 1008 Wien ISSN 1997-8308, Universimed CMC GmbH, Markgraf-Rüdiger-Straße 6–8, 1150 Wien Offizielles Medium der ÖGO, ÖGU und ÖGOuT 2 / 2018 Orthopädie & Traumatologie www.universimed.com Rheumatologie © iStockphoto.com/video-doctor © iStockphoto.com/video-doctor Knochengesundheit | Seite 9 Osteoporose in der orthopädischen Praxis Wirbelsäulenchirurgie | Seite 26 Der zervikothorakale Übergang – eine besondere Herausforderung ACR/ARHP | Seite 57 Good News from San Diego Inserat_A4 19.12.17 13:08 Seite 1 26. OSTEOPOROSE FORUM 3. - 5. Mai 2018 St. Wolfgang Eventresort Hotel scalaria Gynäkologie, Orthopädie und Knochen Tagungspräsidentin: Neue Leitlinien: Univ.-Doz. Dr. Astrid Fahrleitner-Pammer DVO Arznei und Vernunft Tagungssekretär: Prim. Dr. Peter Bernecker Knochen, Niere, Gefäße Ernährung und Knochen Neues und „Hands on“ in der Osteologie Kongress-Büro: Aus der Praxis Wiener Medizinische Akademie, Alser Straße 4, 1090 Wien für die Praxis T: +43 1 405 1383-17 F: +43 1 4078274 E: [email protected] Fachausstellung: Hotelreservierung: „Rare bone MAW - Medizinische Ausstellungs- Reisebüro PRO TRAVEL diseases” und Werbegesellschaft Pilgerstraße 152 Freyung 6, 1010 Wien 5360 St.Wolfgang Sekundäre T: +43 1 53663-48 F: +43 1 5356016 T: +43 6138 25250 Osteoporose E: [email protected], [email protected] F: +43 6138 3054 www.medacad.org/osteoporose2018 Editorial G. Holzer, Wien ORTHOPÄDIE & TRAUMATOLOGIE RHEUMATOLOGIE Osteoporose und ihre sekundäre Prophylaxe Die Osteoporose wird auch als „silent disease“ – als stille nur mehr etwa die Hälfte nach wie vor unter einer Therapie Erkrankung – bezeichnet. Das ist ein Grund dafür, dass sie befindet. Das ist dramatisch.
    [Show full text]
  • Download Jahresbericht Kantonsapotheke 2014
    Kanton Zürich Gesundheitsdirektion Kantonsapotheke 205. Jahresbericht Kantonsapotheke Zürich 2014 205. Jahresbericht Kantonsapotheke Zürich 2014 Während 24 Stunden an 365 Tagen im Jahr – die Kantonsapotheke ist ein verlässlicher Partner im Gesundheitswesen für • Patienten • Spitäler • Heime • Rettungsorganisationen • Ärzte • Pflegepersonal • Bevölkerung • Industrie Allgemeines Die Kantonsapotheke Zürich (KAZ) ist als Dienst- Die Kantonsapotheke Zürich arbeitet eng mit ihren leistungsbetrieb der Gesundheitsdirektion des Kantons Partnern zusammen, sie ist vor Ort und in die Prozesse Zürich Partnerin des Universitätsspitals Zürich (USZ), integriert. Wir kennen und erfüllen den Bedarf unserer des Kantonsspitals Winterthur (KSW), der Psychiat- Partner. Da wir über das aktuellste pharmazeutische rischen Universitätsklinik (PUK) und verschiedener Wissen verfügen, können wir stets objektive fachliche kantonaler Krankenhäuser und Institute. Als eines der Beratung für alle Anspruchsgruppen gewährleisten. führenden spitalpharmazeutischen Kompetenzzentren der Schweiz verfügt sie über einen gesetzlichen Der Jahresbericht gibt einen Einblick in die im Jahr Versorgungsauftrag. Die Kantonsapotheke erbringt 2014 erbrachten Leistungen im Rahmen unserer ein breites Spektrum von Leistungen rund um das Kernkompetenzen Heilmittel auf dem höchstmöglichen Niveau bezüglich Qualität und Wirtschaftlichkeit. Dabei orientieren • Fachberatung und Wissensvermittlung wir uns an den neusten Technologien und setzen • Versorgungskette aktuellstes pharmazeutisches Know-how
    [Show full text]
  • Original Adverse Drug Reactions of Antineoplastic And
    Adverse drug reactions of antineoplastic and immunomodulating agents reported to the Egyptian Pharmaceutical Vigilance Center Original Samar O. Gouda1, Amr A. Saad2, Maggie M. Abbassi1, and Samar F. Farid1 Article 1Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University 2Egyptian Pharmaceutical Vigilance Center ABSTRACT The aim of this study was to evaluate the pattern of Adverse Drug Reactions (ADRs) related to antineoplastic and immunomodulating agents in Egypt. We extracted all ADR reports of antineoplastic and immunomodulating agents (Anatomical Therapeutic Chemical (ATC) code L) that were reported to Egyptian Pharmaceutical Vigilance Center (EPVC) from January 2011 to December 2015 using VigiLyze TM. Afterwards, these reports were analyzed and categorized by age, sex, reporter qualification, seriousness, type of ADRs, medications, indications of use and causality. During the study period, 1905 reports related to antineoplastic and immunomodulating agents were received; 44.6% of which were reported by consumers and 56.8% by health care professionals. ADRs were serious in 13.3% and 65.1% of the cases reported by consumers and healthcare professionals, respectively. Approximately half (52.5%) of the reported ADRs occurred in females and only 8.4% occurred in children. Half of the reported ADRs ( 51.5%) occurred in middle aged group (45- 64 years). The most reported classes at the therapeutic level were immunostimulants (ATC code L03) and antineoplastic agents (ATC code L01). The most frequently reported medication was peg-interferon alfa-2a. The majority of ADRs were of the type "general disorders and administration site conditions" and "gastrointestinal disorders". In conclusion, ADRs caused by immunostimulants especially interferons have higher tendency to be reported in Egypt especially in the middle-aged group.
    [Show full text]
  • Orphan Drugs Regulatory Framework, Market Positioning and Major Development Challenges and Strategies
    Inês Patrícia Ferreira Amaral ORPHAN DRUGS REGULATORY FRAMEWORK, MARKET POSITIONING AND MAJOR DEVELOPMENT CHALLENGES AND STRATEGIES Dissertação de Mestrado em Biotecnologia Farmacêutica, orientada pela Professora Doutora Maria Dulce Cotrim e pela Doutora Ana Catarina Pinto (Bluepharma, Indústria Farmacêutica SA) e apresentada à Faculdade de Farmácia da Universidade de Coimbra Julho 2016 Inês Patrícia Ferreira Amaral ORPHAN DRUGS REGULATORY FRAMEWORK, MARKET POSITIONING AND MAJOR DEVELOPMENT CHALLENGES AND STRATEGIES Dissertação de Mestrado em Biotecnologia Farmacêutica, orientada pela Professora Doutora Maria Dulce Cotrim e pela Doutora Ana Catarina Pinto (Bluepharma, Indústria Farmacêutica SA) e apresentada à Faculdade de Farmácia da Universidade de Coimbra Julho 2016 Agradecimentos Nesta fase várias foram as pessoas que passaram na minha vida e por uma ou por outra razão deixaram um pequeno pedaço de si. No entanto quero agradecer, em particular: À Professora Doutora Maria Dulce Cotrim, Professora da Faculdade de Farmácia da Universidade de Coimbra, por se ter disponibilizado para orientar esta dissertação. Ao Professor Doutor Sérgio Simões, Professor da Faculdade de Farmácia da Universidade de Coimbra e Chairman da Luzitin S.A, por me ter dado o prazer de concretizar este trabalho em parceria com a Luzitin. À Doutora Ana Catarina Pinto, orientadora desta dissertação na Luzitin, por toda a disponibilidade, dedicação, apoio incondicional, compreensão ao longo do trabalho e principalmente por estar sempre presente na orientação desta minha dissertação. Aos meus pais, que vivem comigo desde sempre as alegrias e tristezas desta caminhada, sem vocês isto não tinha sentido. Agradeço todo o esforço que fazem para tornarem possível a realização dos meus desejos, por todos os valores que me transmitem e toda a preocupação que têm comigo.
    [Show full text]